These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26875576)

  • 41. Linezolid: in infants and children with severe Gram-positive infections.
    Lyseng-Williamson KA; Goa KL
    Paediatr Drugs; 2003; 5(6):419-29; discussion 430-1. PubMed ID: 12765493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis.
    Colli A; Campodonico R; Gherli T
    Ann Thorac Surg; 2007 Jul; 84(1):87-91. PubMed ID: 17588391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience.
    McKinnell JA; Arias CA
    Clin Infect Dis; 2015 Sep; 61(6):879-82. PubMed ID: 26063714
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.
    Kato-Hayashi H; Niwa T; Ohata K; Harada S; Matsumoto T; Kitagawa J; Tsurumi H; Suzuki A
    J Clin Pharm Ther; 2019 Dec; 44(6):888-894. PubMed ID: 31373043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
    Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
    Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
    Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
    Chien JW; Kucia ML; Salata RA
    Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linezolid and vancomycin-resistant Enterococcus faecium peritonitis in a child after liver transplantation.
    García-Gil V; Gómez-Gil MR; Escosa-García L; Hierro-Llanillo L
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):66. PubMed ID: 25063448
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients.
    Kang Y; Vicente M; Parsad S; Brielmeier B; Pisano J; Landon E; Pettit NN
    Transpl Infect Dis; 2013 Oct; 15(5):466-73. PubMed ID: 23911080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials.
    An MM; Shen H; Zhang JD; Xu GT; Jiang YY
    Int J Antimicrob Agents; 2013 May; 41(5):426-33. PubMed ID: 23537580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
    Patel K; Kabir R; Ahmad S; Allen SL
    J Oncol Pharm Pract; 2016 Apr; 22(2):212-8. PubMed ID: 25326010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
    Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical experience with linezolid in the treatment of resistant gram-positive infections.
    Antony SJ; Diaz-Vasquez E; Stratton C
    J Natl Med Assoc; 2001 Oct; 93(10):386-91. PubMed ID: 11688919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
    Patel R; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.